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ABSTRACT 
 
Background: 
The aim of this study was to assess the clinical effectiveness of the long-acting injectable 
antipsychotic paliperidone palmitate using treatment continuation at one year as an outcome. 
 
Methods: 
Patients were initiated on paliperidone palmitate prior to December 2014 in a single health 
board in Wales (UK). Demographic factors which may have influenced outcome were 
analysed. For patients completing one year of treatment, inpatient stay in the 12 months prior 
to and following paliperidone palmitate initiation was compared. 
 
Results: 
Data were available for 64 patients, 41 had a diagnosis of schizophrenia and seven had 
previously received clozapine. Continuation rates at six and 12 months were 69% and 63% 
respectively. Treatment continuation was not associated with demographic factors. For 
continuers, mean inpatient stay prior to and post initiation was 83.2±105.3 and 73.5±103.3 
days respectively (p=0.61). The most common reason for discontinuation was lack of effect 
(n=9). 
 
Conclusions: 
The proportion of patients remaining on treatment was comparable to that reported in other 
naturalistic studies. Prescribing for indications outside the product license was relatively 
common, although this did not appear to influence outcome. Treatment continuation at six 
months appeared to be a predictor of longer-term outcome. 
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Introduction: 
Schizophrenia is a chronic, relapsing, severe mental illness associated with significant 
morbidity and mortality. The long-term management of schizophrenia may be limited by non-
compliance with antipsychotic medication, which has been shown to be a significant factor in 
relapse and rehospitalisation (Ayuso-Gutierrez & del Rio Vega, 1997). Long-acting injectable 
formulations of antipsychotics (dopamine D2 receptor antagonists or partial agonists) have 
been developed as a possible mechanism to address covert non-compliance, and may have 
some advantages over oral therapy in the management of this chronic relapsing condition 
(Alphs, et al., 2016). However, the influence of factors which might affect outcome, such as 
optimal dosing interval, remain to be fully investigated (Kisely, et al., 2015). Risperidone was 
the first of the newer, atypical antipsychotics to be formulated as a long-acting injection. Due 
to its pharmacokinetic properties, risperidone long-acting injection (RLAI) must be 
administered on a fortnightly basis (Eerdekens, et al., 2004). The active risperidone 
metabolite, 9-OH-risperidone, has been shown to have high affinity for the dopamine D2 and 
serotonin 5-HT2A receptors (Schotte, et al., 1996), and has been marketed as the atypical 
antipsychotic, paliperidone. A long acting injectable formulation of paliperidone as the 
palmitate salt received marketing authorisation (formerly known as the product licence) in the 
UK in 2011 and had the possible advantage of a pharmacokinetic profile which allowed 
monthly dosing (Samtani, et al., 2009). 
 
The efficacy of paliperidone palmitate (PP) in the treatment of schizophrenia has been 
investigated in randomised controlled trials (RCTs). PP has shown evidence of benefit over 
placebo (Pandina, et al., 2010) and comparable efficacy and tolerability to RLAI (Pandina, et 
al., 2011). Whilst the methodology employed in RCTs allows assessment of the efficacy of 
interventions, such studies may not be generalizable to clinical practice. The strict inclusion 
and exclusion criteria result in participants being unrepresentative of real world patients. 
Moreover, short study durations may not be adequate to assess the long-term effectiveness 
of medicines intended for the treatment of chronic conditions (Stroup, et al., 2003). 
Naturalistic observational studies (e.g (Attard, et al., 2014) (Deslandes, et al., 2015), and 
studies designed with pragmatic outcome measures such as treatment continuation (Stroup, 
et al., 2003) have provided evidence of the effectiveness of antipsychotics in settings more 
relevant to clinical situations. The aim of the present study was to assess the effectiveness of 
PP in a clinical setting using treatment continuation at one year as an outcome measure. 
 
Methods: 
Design 
This was a retrospective, naturalistic, one year follow-up study of patients receiving PP in a 
single health board in Wales (UK), in both hospital inpatient and outpatient settings. For 
patients completing one year of treatment, a mirror-image comparison of hospital inpatient 
stay, in the 12 months prior to and following PP initiation was conducted. Data were collected 
from pharmacy records and by retrospective case-note review during November and 
December 2015. The health board quality improvement department and mental health 
clinical board approved the study. 
 
Participants and outcome measures 
All patients initiated on PP prior to December 2014 in a single health board in Wales were 
identified from pharmacy records and included in the study. Patients were classified as 
“continuers” (those completing 12 months on PP treatment), or “discontinuers” (those 
discontinuing within 12 months of initiation). Demographic factors which may have influenced 
treatment outcome including age at initiation, diagnosis (schizophrenia vs other indications 
including schizoaffective disorder), gender, previous antipsychotic, inpatient or outpatient 
status on initiation, prior clozapine treatment, two previous antipsychotic treatment failures 
and recreational drug use were recorded. The duration of hospital stay in the 12 months prior 
to and post PP initiation was used as a measure of treatment effectiveness in treatment 
continuers. For discontinuers, reasons for treatment discontinuation (as described in patient 
records), dose at discontinuation and the antipsychotic to which they were switched were 
noted. Prior treatment with clozapine was considered an indication of treatment refractory 
illness. 
 
Statistical analysis 
Demographic factors which may have influenced treatment outcome were analysed using 
unpaired Student t-test for continuous variables and Fisher’s Exact test for categorical data. 
The number of days spent as an inpatient prior to and following PP initiation was compared 
using paired Student t-test. All statistical analyses were conducted using GraphPad Prism 
version 6.0 (GraphPad Software, La Jolla, CA, USA). 
 
Results: 
Sixty-six patients received PP, of whom two moved abroad during the follow-up period and 
were lost to follow-up. Accordingly, one year outcome data were available for a total of 64 
patients. Patient demographics are shown in table 1; 41 (36%) patients had a diagnosis of 
schizophrenia, the other common diagnoses were schizoaffective disorder (n=5; 8%), bipolar 
disorder (n=5; 8%) and persistent delusional disorder (n=4; 6%). Seven (11%) patients had 
previously received clozapine, and 49 (76%) were switched to PP from risperidone (either 
oral or long-acting injection). The proportion of patients remaining on treatment over time is 
shown in figure 1; forty (63%) patients remained on PP at one year. 
 
Continuers 
Treatment continuation (vs treatment discontinuation) was not associated with age at 
initiation (P=0.054 unpaired student t-test), diagnosis, gender, previous risperidone treatment 
vs other antipsychotic, inpatient/outpatient status on initiation, prior clozapine treatment, two 
previous treatment failures or recreational drug use (p=0.79; p=1.0; p=0.38; p=1.0; p=0.41; 
p=0.44 and p=0.43 respectively, Fisher’s Exact test). In regard to patients completing one 
year on PP, the mean time spent as an inpatient in the 12 months prior to PP initiation was 
83.2 ± 105.3 days, and in the 12 months post PP initiation it was 73.5 ± 103.3 days (p=0.61, 
paired student t-test). 
 
Discontinuers 
Twenty-four patients discontinued PP within one year, 12 of whom discontinued between 90 
and 120 days and four of whom discontinued between 120 and 365 days (see figure 1). 
Mean dose at discontinuation, reasons for discontinuation and antipsychotic treatment post 
discontinuation are shown in table 2. The most common reason for discontinuation was 
perceived lack of effect (n=9). The doses at discontinuation for these patients were 100mg 
(n=4) and 150mg (n=5), (mean=127.8mg), and the antipsychotics prescribed post PP were 
clozapine (n=7), flupenthixol decanoate (n=1) and amisulpride (n=1). Seven patients 
discontinued due to adverse effects, which encompassed weight gain (n=2), extra-pyramidal 
side effect (n=2), sexual dysfunction (n=2) and sedation (n=1). Of the five patients switching 
from risperidone to PP due to a lack of effect, 3 had discontinued PP at one year due to lack 
of effect (the other two patients continued on PP treatment). 
 
Discussion: 
This study assessed the effectiveness of PP in clinical practice using treatment continuation 
at 12 months as an outcome measure. Of the 64 patients who were included in the study, 40 
(63%) remained on treatment (classified as “continuers”) at one year. There were no 
significant differences in demographic factors between continuers and patients discontinuing 
PP, therefore baseline characteristics did not appear to influence treatment outcome in this 
study. The majority (83%) of patients who discontinued treatment did so within the first 180 
days, therefore completion of six months treatment appeared to be a good indicator of 
continuation at one year. In the case of treatment continuers, there was no significant 
difference in inpatient stay in the 12 months prior to and post PP initiation. The most common 
reason for treatment discontinuation was lack of effect.  
 
The proportion of patients remaining on treatment was comparable to the 65% (Attard, et al., 
2014) and 60% (Whale, et al., 2015) reported in similar one-year naturalistic studies of PP.  
One study comparing the outcomes of patients treated with PP, RLAI and zuclopentixol 
decanoate reported a somewhat lower continuation rate of PP (48%), albeit over a longer 18 
month follow-up period (Cordiner, et al., 2016). Continuation with PP was noticeably higher 
than that seen at the same time point in a similar study of RLAI (45%) in our health board 
(Deslandes, et al., 2009) and that observed in another study of RLAI in the UK (Taylor, et al., 
2009). However, it must be noted that the observational nature of these studies does not 
allow direct comparisons to be made. In the case of continuers, there was no significant 
difference in the number of days spent as an inpatient in the 12 months prior to and following 
PP initiation. This was in contrast to other similar naturalistic studies of PP which revealed a 
reduction in hospital admissions and inpatient stay post initiation in hospital in the UK 
(Taylor, et al., 2016) (Nikolic, et al., 2017) albeit over longer periods (two and three years 
post PP initiation respectively) than seen in our study. Two one year mirror image studies, 
one from Canada (Vincent, et al., 2017) and one from the UK (Bressington, et al., 2015), 
showed a non-significant reduction in hospitalisation days when using first PP injection as 
the mirror point, suggesting that study duration may be an important factor when measuring 
this outcome. 
 
None of the demographic factors analysed in this study appeared to influence treatment 
outcome. This was in contrast to the findings of other studies of PP which found that 
outpatient status on initiation, switching from risperidone (Attard, et al., 2014) and a 
diagnosis of schizophrenia (Whale, et al., 2015) were associated with treatment continuation 
at one year. Similarly, outpatient initiation and switching from risperidone have also been 
shown to predict PP continuation at two years (Taylor, et al., 2016). The relatively small 
number of subjects in our study may be an explanation for these differences. Prescribing for 
indications outside of the marketing authorisation accounted for 36% of patients in our study. 
In part, this may reflect the more limited indications of the long-acting injectable paliperidone 
preparation compared to the oral equivalent. However, it also highlights the relatively 
common phenomenon of off-label prescribing within the field of psychiatry. Nevertheless, 
patients treated for conditions other than schizophrenia were no more likely to discontinue at 
one year, providing some evidence for the effectiveness of PP in this group. Although 
demographic factors were not associated with outcome, treatment continuation at six months 
appeared to be conducive to or suggestive of continuation at one year. The majority (83%) of 
patients who discontinued PP did so within six months of treatment initiation, whilst 91% of 
those completing six months went on to complete one year. This was largely in accordance 
with a more long-term finding that completion of one year of treatment with RLAI or oral 
aripiprazole was an indicator of subsequent continuation at five years in a natuaralistic cohort 
(Deslandes, et al., 2015).  A perceived lack of effect was the most common reason for 
discontinuation, consistent with other naturalistic studies (Attard, et al., 2014) (Whale, et al., 
2015) (Cordiner, et al., 2016) and accounted for 14% of the total sample. Despite lack of 
effect being the reason for discontinuation, 4/9 (56%) of these patients did not receive the 
maximum licensed dose of PP (150mg), whilst 3/9 (33%) had previously been treated with 
clozapine. Therefore 6/9 individuals might have been expected to experience a poor 
response due to sub-optimal dosing or a history of treatment refractory illness. PP appeared 
to have similar tolerability to that seen in our previous study of RLAI with seven (11%) of the 
64 patients discontinuing due to adverse effects, compared with 10% reported by 
(Deslandes, et al., 2009). In this context, other naturalistic studies of PP have reported both 
lower (5%) (Attard, et al., 2014) and slightly higher (13%) (Cordiner, et al., 2016) levels of 
discontinuation due to adverse effects. 
 
Patient choice was the reason for PP initiation in 16 patients, 14 of whom chose PP on the 
basis of monthly rather than fortnightly dosing when switching from RLAI. However, this did 
not appear to influence outcome, with similar proportions of both continuers and 
discontinuers (25%) switching to PP for this reason. Furthermore, of the six of these patients 
who subsequently discontinued, three did so due to refusal of PP. Despite the chemical and 
pharmacological similarities between paliperidone and risperidone, five patients switched to 
PP from oral risperidone or RLAI due to lack of effect. The rationale for this was the higher 
licensed dose equivalence of PP (150mg/month) compared with RLAI (100mg/month). This 
did not appear to influence outcome however, with three of the five patients subsequently 
discontinuing PP due to lack of effect. Across the whole study cohort the mean PP dose at 
end point was only slightly greater than 100mg, however approximately 30% of continuers 
received 150mg and therefore a higher equivalent dose than could have been achieved 
within the RLAI license.  
 
This was a retrospective, naturalistic, observational study, and the methodological limitations 
were common to many such studies. There was no comparator group, no formal assessment 
of mental state nor randomisation, therefore any conclusions must be treated with a degree 
of caution. However, the study does report outcomes in real world patients (many of which 
would have been excluded from RCTs), being treated for both licensed and unlicensed 
indications and with an extended period of follow-up. PP appeared to show equivalent 
effectiveness in both schizophrenia and other indications. This may offer some reassurance 
to prescribers given the relatively common use of PP for indications outside the product 
license. However, it must be noted that the study was not designed to compare the outcomes 
of these two groups, and possible differences in the populations do not allow direct 
comparisons to be performed. Although the overall continuation rate seen in this study was 
only 63%, the subsequent completion rate for those who remained on treatment at six 
months (91%) was encouraging and suggested that outcome at six months may be a useful 
indicator of longer-term treatment continuation. 
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Table 1. Patient demographics, reasons for initiation and dose at study endpoint. 
 
 
All 
patients 
(n=64) 
Continuers 
(n=40) 
Discontinuers 
(n=24) 
 
 Age at initiation, yrs 
Mean ± sd 
Range 
 
43.8 ± 
15.3 
18–79 
 
46.6 ± 
15.7 
21–79 
 
39.0 ± 13.6 
18–78 
Gender, n (%) 
Male 45 (70) 28 (70) 17 (71) 
Previous clozapine, n (%) 7 (11) 3 (8) 4 (17) 
2 previous treatment failures, 
n (%) 38 (59) 22 (55) 16 (67) 
Indication, n (%) 
Schizophrenia 
Other 
 
41 (64) 
23 (36) 
 
25 (63) 
15 (38) 
 
16 (67) 
 8 (33) 
Inpatient on initiation, n (%) 39 (61) 24 (60) 15 (63) 
Recreational drug use, n (%) 23 (36) 16 (40) 7 (29) 
Switched from, n (%) 
Risperidone po 
Risperidone IM 
Other antipsychotic 
 
20 (31) 
29 (45) 
15 (23) 
 
11 (28) 
18 (45) 
11 (28) 
 
 9 (38) 
11 (46) 
 4 (17) 
Reason for initiation, n (%) 
Previous non-compliance 
Patient choice 
Previous poor response 
Previous side effect 
 
30 (47) 
16 (25) 
13 (20) 
5 (8) 
 
20 (50) 
10 (25) 
7 (18) 
3 (8) 
 
10 (42) 
6 (25) 
6 (25) 
2 (8) 
 
 
Dose at end point, mg/month 
Mean ± sd 
          Range 
 
 
109.4 ± 
33.2 
50–150 
 
107.5 ± 
33.6 
50–150 
 
112.5 ± 33.0 
50–150 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Reasons for discontinuation and antipsychotic post PP 
 
 
All 
discontinuers 
(n=24) 
Previous 
clozapine 
(n=4) 
Previous 
non-clozapine 
(n=20) 
Dose at discontinuation, mg 
Mean ± sd 
Range 
 
112.5 ± 33.0 
50–150 
 
125.0 ± 28.9 
100–150 
 
110.0 ± 33.8 
50–150 
Reason for discontinuation, n (%) 
Lack of effect 
Side effect 
Patient refused 
Patient choice 
Patient death 
 
9 (38) 
7 (29) 
4 (17) 
3 (13) 
1 (4) 
 
3 (75) 
1 (25) 
– 
– 
– 
 
6 (30) 
6 (30) 
4 (20) 
3 (15) 
1 (5) 
Switched to, n (%) 
Clozapine 
Atypical po (not clozapine) 
Atypical IM 
Typical IM 
No antipsychotic 
 
9 (38) 
5 (21) 
3 (13) 
1 (4) 
6 (25) 
 
2 (50) 
– 
1 (25) 
1 (25) 
– 
 
7 (35) 
5 (25) 
2 (10) 
– 
6 (30) 
 
 
 
 
 
 
 
 
Figure 1. Percentage of patients remaining on treatment over time; grouped according to 
whether they had received previous clozapine treatment (PC) or had not received previous 
clozapine treatment (non PC) 
